New onset of generalized myasthenia gravis developed after a new coronavirus infection (COVID-19)
https://doi.org/10.22625/2072-6732-2021-13-4-127-132
Abstract
Development of various immune-mediated neurological complications after a viral infection is of particular interest to medical society during a pandemic of COVID-19. It was found that SARS-CoV-2 has the ability to cause hyperstimulation of the immune system, thereby initiating developing of autoimmune diseases. The article describes a clinical case of new onset of generalized myasthenia gravis with thymoma in a patient after previous COVID-19.
About the Authors
T. M. AlekseevaRussian Federation
Saint-Petersburg
P. Sh. Isabekova
Russian Federation
Saint-Petersburg
M. P. Topuzova
Russian Federation
Saint-Petersburg
N. V. Skripchenko
Russian Federation
Saint-Petersburg
References
1. Ruan Q. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [Electronic resource] / Ruan Q. [et al.] // Intensive Care Medicine. — 2020. — Vol. 46, № 5. — P. 846-848.
2. Rojas M. Molecular mimicry and autoimmunity [Electronic resource] / M. Rojas [et al.] // Journal of Autoimmunity. — 2018. — Vol. 95. — P. 100-123.
3. Vojdani A. Potential antigenic cross-reactivity between SARSCoV-2 and human tissue with a possible link to an increase in autoimmune diseases [Electronic resource] / Vojdani A., Kharrazian D. // Clinical Immunology. — 2020. — Vol. 217. — P. 108480.
4. Vanderlugt C. L. Epitope spreading in immune-mediated diseases: implications for immunotherapy [Electronic resource] / Vanderlugt C.L., Miller S.D. // Nature Reviews Immunology. — 2002. — Vol. 2, № 2. — P. 85-95.
5. Ercolini A. M. The role of infections in autoimmune disease [Electronic resource] / Ercolini A.M., Miller S.D. // Clinical & Experimental Immunology. — 2009. — Vol. 155, № 1. — P. 1-15.
6. Kiseleva E.P. Molekulyarny`e mexanizmy` iniciirovaniya i modulyacii autoimmunnogo processa mikroorganizmami / Kiseleva E.P., Mixajlopulo K.I., Novik G.I. // Voprosy` gematologii/onkologii i immunopatologii v pediatrii. – 2021. – T. 20, №1. – S. 99-113 (in Russian).
7. Kim D. The Architecture of SARS-CoV-2 Transcriptome [Electronic resource] / Kim D. [et al.] // Cell. — 2020. — Vol. 181, № 4. — P. 914-921.
8. Català A. Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study [Electronic resource] / Català A. [et al.] // Dermatologic Therapy. — 2020. — Vol. 33, № 6.
9. Cao Y. Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GMCSF and Diminished IL-10 Production [Electronic resource] / Cao Y. [et al.] // The Journal of Immunology. — 2016. — Vol. 196, № 5. — P. 2075-2084.
10. Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia [Electronic resource] / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol. 40, №6. Р. 1577–1589.
11. Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W. [et al.] // Cell Mol Immunol. – 2020. – Vol. 17. P. 650–652.
12. Romero-Sanchez C.M. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry / Romero-Sanchez C.M. [et al.] // Neurology. – 2020. – Vol. 95. P. 1060–1070.
13. Willison H.J. Guillain-Barré syndrome / Willison H.J., Jacobs B.C., van Doorn P.A. // Lancet. – 2016. – Vol. 13, №388. Р. 717-727.
14. Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S., Daimee M., Sultan S. // J Neurol. – 2021. – Vol. 268, №8. P. 2690-2696.
15. Huber M. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient [Electronic resource] / Huber M. [et al.] // Front Neurol. – 2020. – Vol. 6, №11.
16. Restivo D.A. Myasthenia Gravis Associated With SARSCoV-2 Infection / Restivo D.A., Centonze D., Alesina A., Marchese-Ragona R. // Ann Intern Med. – 2020. – Vol. 15. P. 1027-1028.
17. Muhammed L. MuSK Antibody-Associated Myasthenia Gravis With SARS-CoV-2 Infection: A Case Report / Muhammed L., Baheerathan A., Cao M., Leite M.I., Viegas S. // Ann Intern Med. – 2021 – Vol. 12. P. 1298.
18. Assini A. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection / Assini A. [et al.] // Eur J Neurol. – 2021 – Vol. 28. P. 3537-3539.
19. Temporary methodological recommendations «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)» Version 7 (03.06.2020) (in Russian).
20. Diorio C. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2 / Diorio C. [et al.] // J. Clin. Invest. – 2020. Vol. 130. P. 5967– 5975.
21. Consiglio C.R. The immunology of multisystem inflammatory syndrome in children with COVID-19 / Consiglio C.R. [et al.] // Cell. – 2020. Vol. 183. P. 968-981.
22. Lobzin Yu.V. Pediatricheskij mul`tisistemny`j vospalitel`ny`j sindrom, associirovanny`j s novoj koronavirusnoj infekciej: nereshenny`e problemy` / Lobzin Yu.V. [i dr.] // Zhurnal Infektologii. – 2021. – T. 13, №1. – S. 13-21 (in Russian).
Review
For citations:
Alekseeva T.M., Isabekova P.Sh., Topuzova M.P., Skripchenko N.V. New onset of generalized myasthenia gravis developed after a new coronavirus infection (COVID-19). Journal Infectology. 2021;13(4):127-132. (In Russ.) https://doi.org/10.22625/2072-6732-2021-13-4-127-132